BioAmber has raised $30m in pre-IPO funding, with $10m coming from chemicals group Lanxess, which has launched a manufacturing partnership with the feedstocks company.
BioAmber, a US-based converter of feedstocks into chemicals, has closed a $30m series C round, the first tranche of which was raised three months ago, shortly before it filed for an initial public offering (IPO) that could raise up to $150m. Investors include conglomerate Mitsui & Co. and chemicals group Lanxess, which provided the second tranche, worth $10m, on 6th February.
Mitsui was joined in the $20m November tranche by venture capital firm Sofinnova Ventures, investment group Naxos Capital Partners…
